Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding

Kathleen R. Markan, Meghan C. Naber, Magdalene K. Ameka, Maxwell D. Anderegg, David J. Mangelsdorf, Steven A. Kliewer, Moosa Mohammadi, Matthew J. Potthoff

Research output: Contribution to journalArticle

198 Citations (Scopus)

Abstract

Fibroblast growth factor (FGF)21 is an endocrine hormone that is expressed in multiple tissues and functions physiologically to maintain energy homeostasis. FGF21 is being pursued as a therapeutic target for diabetes and obesity because of its rapid and potent effects on improving insulin sensitivity. However, whether FGF21 enhances insulin sensitivity under physiologic conditions remains unclear. Here, we show that liver-derived FGF21 enters the circulation during fasting but also remains present and functional during the early stage of refeeding. After a prolonged fast, FGF21 acts as an insulin sensitizer to overcome the peripheral insulin resistance induced by fasting, thereby maximizing glucose uptake. Likewise, FGF21 is produced from the liver during overfeeding and mitigates peripheral insulin resistance. DIO FGF21 liver-speci fic knockout, but not FGF21 adipose-specific knockout, mice have increased insulin resistance and decreased brown adipose tissue-mediated glucose disposal. These data are compatible with the concept that FGF21 functions physiologically as an insulin sensitizer under conditions of acute refeeding and overfeeding.

Original languageEnglish (US)
Pages (from-to)4057-4063
Number of pages7
JournalDiabetes
Volume63
Issue number12
DOIs
StatePublished - Dec 1 2014

Fingerprint

Glucose
Liver
Insulin Resistance
Vascular Resistance
Fasting
Insulin
fibroblast growth factor 21
Brown Adipose Tissue
Knockout Mice
Homeostasis
Obesity
Hormones

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. / Markan, Kathleen R.; Naber, Meghan C.; Ameka, Magdalene K.; Anderegg, Maxwell D.; Mangelsdorf, David J.; Kliewer, Steven A.; Mohammadi, Moosa; Potthoff, Matthew J.

In: Diabetes, Vol. 63, No. 12, 01.12.2014, p. 4057-4063.

Research output: Contribution to journalArticle

Markan, KR, Naber, MC, Ameka, MK, Anderegg, MD, Mangelsdorf, DJ, Kliewer, SA, Mohammadi, M & Potthoff, MJ 2014, 'Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding', Diabetes, vol. 63, no. 12, pp. 4057-4063. https://doi.org/10.2337/db14-0595
Markan, Kathleen R. ; Naber, Meghan C. ; Ameka, Magdalene K. ; Anderegg, Maxwell D. ; Mangelsdorf, David J. ; Kliewer, Steven A. ; Mohammadi, Moosa ; Potthoff, Matthew J. / Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. In: Diabetes. 2014 ; Vol. 63, No. 12. pp. 4057-4063.
@article{170aa2e4b1f24587ac8f21883cc5d1eb,
title = "Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding",
abstract = "Fibroblast growth factor (FGF)21 is an endocrine hormone that is expressed in multiple tissues and functions physiologically to maintain energy homeostasis. FGF21 is being pursued as a therapeutic target for diabetes and obesity because of its rapid and potent effects on improving insulin sensitivity. However, whether FGF21 enhances insulin sensitivity under physiologic conditions remains unclear. Here, we show that liver-derived FGF21 enters the circulation during fasting but also remains present and functional during the early stage of refeeding. After a prolonged fast, FGF21 acts as an insulin sensitizer to overcome the peripheral insulin resistance induced by fasting, thereby maximizing glucose uptake. Likewise, FGF21 is produced from the liver during overfeeding and mitigates peripheral insulin resistance. DIO FGF21 liver-speci fic knockout, but not FGF21 adipose-specific knockout, mice have increased insulin resistance and decreased brown adipose tissue-mediated glucose disposal. These data are compatible with the concept that FGF21 functions physiologically as an insulin sensitizer under conditions of acute refeeding and overfeeding.",
author = "Markan, {Kathleen R.} and Naber, {Meghan C.} and Ameka, {Magdalene K.} and Anderegg, {Maxwell D.} and Mangelsdorf, {David J.} and Kliewer, {Steven A.} and Moosa Mohammadi and Potthoff, {Matthew J.}",
year = "2014",
month = "12",
day = "1",
doi = "10.2337/db14-0595",
language = "English (US)",
volume = "63",
pages = "4057--4063",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "12",

}

TY - JOUR

T1 - Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding

AU - Markan, Kathleen R.

AU - Naber, Meghan C.

AU - Ameka, Magdalene K.

AU - Anderegg, Maxwell D.

AU - Mangelsdorf, David J.

AU - Kliewer, Steven A.

AU - Mohammadi, Moosa

AU - Potthoff, Matthew J.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Fibroblast growth factor (FGF)21 is an endocrine hormone that is expressed in multiple tissues and functions physiologically to maintain energy homeostasis. FGF21 is being pursued as a therapeutic target for diabetes and obesity because of its rapid and potent effects on improving insulin sensitivity. However, whether FGF21 enhances insulin sensitivity under physiologic conditions remains unclear. Here, we show that liver-derived FGF21 enters the circulation during fasting but also remains present and functional during the early stage of refeeding. After a prolonged fast, FGF21 acts as an insulin sensitizer to overcome the peripheral insulin resistance induced by fasting, thereby maximizing glucose uptake. Likewise, FGF21 is produced from the liver during overfeeding and mitigates peripheral insulin resistance. DIO FGF21 liver-speci fic knockout, but not FGF21 adipose-specific knockout, mice have increased insulin resistance and decreased brown adipose tissue-mediated glucose disposal. These data are compatible with the concept that FGF21 functions physiologically as an insulin sensitizer under conditions of acute refeeding and overfeeding.

AB - Fibroblast growth factor (FGF)21 is an endocrine hormone that is expressed in multiple tissues and functions physiologically to maintain energy homeostasis. FGF21 is being pursued as a therapeutic target for diabetes and obesity because of its rapid and potent effects on improving insulin sensitivity. However, whether FGF21 enhances insulin sensitivity under physiologic conditions remains unclear. Here, we show that liver-derived FGF21 enters the circulation during fasting but also remains present and functional during the early stage of refeeding. After a prolonged fast, FGF21 acts as an insulin sensitizer to overcome the peripheral insulin resistance induced by fasting, thereby maximizing glucose uptake. Likewise, FGF21 is produced from the liver during overfeeding and mitigates peripheral insulin resistance. DIO FGF21 liver-speci fic knockout, but not FGF21 adipose-specific knockout, mice have increased insulin resistance and decreased brown adipose tissue-mediated glucose disposal. These data are compatible with the concept that FGF21 functions physiologically as an insulin sensitizer under conditions of acute refeeding and overfeeding.

UR - http://www.scopus.com/inward/record.url?scp=84911917697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911917697&partnerID=8YFLogxK

U2 - 10.2337/db14-0595

DO - 10.2337/db14-0595

M3 - Article

VL - 63

SP - 4057

EP - 4063

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 12

ER -